{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T15:46:45Z","timestamp":1772034405050,"version":"3.50.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["STO 1260\/1-1"],"award-info":[{"award-number":["STO 1260\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013865","name":"Stiftung Charit\u00e9","doi-asserted-by":"crossref","award":["none"],"award-info":[{"award-number":["none"]}],"id":[{"id":"10.13039\/501100013865","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["SCHO 1386\/2-1"],"award-info":[{"award-number":["SCHO 1386\/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100015539","name":"Commonwealth Government of Australia","doi-asserted-by":"crossref","award":["none"],"award-info":[{"award-number":["none"]}],"id":[{"id":"10.13039\/100015539","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s11906-019-0934-y","type":"journal-article","created":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T07:31:23Z","timestamp":1554363083000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Pathogenesis of Familial Hyperaldosteronism Type II: New Concepts Involving Anion Channels"],"prefix":"10.1007","volume":"21","author":[{"given":"Michael","family":"Stowasser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Wolley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aihua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard D.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Schewe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"St\u00f6lting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute I.","family":"Scholl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,4]]},"reference":[{"issue":"22","key":"934_CR1","first-page":"1109","volume":"95","author":"DJ Sutherland","year":"1966","unstructured":"\u2022 Sutherland DJ, Ruse JL, Laidlaw JC. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J. 1966;95(22):1109\u201319 This was the first description of familial PA (FH-I).","journal-title":"Can Med Assoc J"},{"issue":"6357","key":"934_CR2","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/355262a0","volume":"355","author":"RP Lifton","year":"1992","unstructured":"\u2022\u2022 Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, et al. A chimaeric 11 beta-hydroxylase\/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 1992;355(6357):262\u20135. \n                      https:\/\/doi.org\/10.1038\/355262a0\n                      \n                     This was the first report of a genetic mutation causing familial PA (FH-I).","journal-title":"Nature"},{"issue":"1","key":"934_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/ng0992-66","volume":"2","author":"RP Lifton","year":"1992","unstructured":"Lifton RP, Dluhy RG, Powers M, Rich GM, Gutkin M, Fallo F, et al. Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase. Nat Genet. 1992;2(1):66\u201374. \n                      https:\/\/doi.org\/10.1038\/ng0992-66\n                      \n                    .","journal-title":"Nat Genet"},{"issue":"6018","key":"934_CR4","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1126\/science.1198785","volume":"331","author":"M Choi","year":"2011","unstructured":"\u2022\u2022 Choi M, Scholl UI, Yue P, Bjorklund P, Zhao B, Nelson-Williams C, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011;331(6018):768\u201372. \n                      https:\/\/doi.org\/10.1126\/science.1198785\n                      \n                     This paper was first to descibe somatic mutations in KCNJ5 within aldosterone-producing adenomas and inherited KCNJ5 mutations in genomic DNA causing familial PA (FH-III).","journal-title":"Science"},{"issue":"7","key":"934_CR5","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1073\/pnas.1121407109","volume":"109","author":"UI Scholl","year":"2012","unstructured":"Scholl UI, Nelson-Williams C, Yue P, Grekin R, Wyatt RJ, Dillon MJ, et al. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. Proc Natl Acad Sci U S A. 2012;109(7):2533\u20138. \n                      https:\/\/doi.org\/10.1073\/pnas.1121407109\n                      \n                    .","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"934_CR6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1161\/HYPERTENSIONAHA.111.183996","volume":"59","author":"P Mulatero","year":"2012","unstructured":"Mulatero P, Tauber P, Zennaro MC, Monticone S, Lang K, Beuschlein F, et al. KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension. 2012;59(2):235\u201340. \n                      https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.111.183996\n                      \n                    .","journal-title":"Hypertension"},{"key":"934_CR7","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Scholl UI, Stolting G, Nelson-Williams C, Vichot AA, Choi M, Loring E, et al. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. elife. 2015;4. \n                      https:\/\/doi.org\/10.7554\/eLife.06315\n                      \n                     This paper first reported genomic CACNA1H mutations as the basis of early onset (including familial) PA (FH-IV).","DOI":"10.7554\/eLife.06315"},{"key":"934_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ebiom.2016.10.002","volume":"13","author":"G Daniil","year":"2016","unstructured":"Daniil G, Fernandes-Rosa FL, Chemin J, Blesneac I, Beltrand J, Polak M, et al. CACNA1H mutations are associated with different forms of primary Aldosteronism. EBioMedicine. 2016;13:225\u201336. \n                      https:\/\/doi.org\/10.1016\/j.ebiom.2016.10.002\n                      \n                    .","journal-title":"EBioMedicine"},{"issue":"9","key":"934_CR9","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/ng.2695","volume":"45","author":"UI Scholl","year":"2013","unstructured":"\u2022\u2022 Scholl UI, Goh G, Stolting G, de Oliveira RC, Choi M, Overton JD, et al. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet. 2013;45(9):1050\u20134. \n                      https:\/\/doi.org\/10.1038\/ng.2695\n                      \n                     This paper reported somatic mutations in CACNA1D within aldosterone-producing adenomas and inherited CACNA1D mutations in genomic DNA causing early onset PA.","journal-title":"Nat Genet"},{"issue":"3","key":"934_CR10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41588-018-0053-8","volume":"50","author":"FL Fernandes-Rosa","year":"2018","unstructured":"\u2022 Fernandes-Rosa FL, Daniil G, Orozco IJ, Goppner C, El Zein R, Jain V, et al. A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism. Nat Genet. 2018;50(3):355\u201361. \n                      https:\/\/doi.org\/10.1038\/s41588-018-0053-8\n                      \n                     This case report described a patient with early onset PA due to a CLCN2 mutation.","journal-title":"Nat Genet"},{"issue":"3","key":"934_CR11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41588-018-0048-5","volume":"50","author":"UI Scholl","year":"2018","unstructured":"\u2022\u2022 Scholl UI, Stolting G, Schewe J, Thiel A, Tan H, Nelson-Williams C, et al. CLCN2 chloride channel mutations in familial hyperaldosteronism type II. Nat Genet. 2018;50(3):349\u201354. \n                      https:\/\/doi.org\/10.1038\/s41588-018-0048-5\n                      \n                     This paper described inherited mutations in CLCN2 as the cause of PA in a large Australian familiy with FH-II and in seven other unrelated probands (one with two other affected family members) with early onset PA and showed that these mutations lead to gain of function, causing zona glomerulosa cell membrane depolarization, and enhanced expression of CYP11B2 (encoding aldosterone synthase).","journal-title":"Nat Genet"},{"issue":"1","key":"934_CR12","first-page":"3","volume":"45","author":"JW Conn","year":"1955","unstructured":"Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1955;45(1):3\u201317.","journal-title":"J Lab Clin Med"},{"issue":"5","key":"934_CR13","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The Management of Primary Aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889\u2013916. \n                      https:\/\/doi.org\/10.1210\/jc.2015-4061\n                      \n                    .","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"934_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1440-1681.1994.tb02519.x","volume":"21","author":"RD Gordon","year":"1994","unstructured":"\u2022 Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol. 1994;21(4):315\u20138 A landmark study drawing attention to the previously unrecognized high prevalence of PA amongst normokalemic hypertensive patients attending a tertiary referral centre.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"11","key":"934_CR15","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","volume":"48","author":"GP Rossi","year":"2006","unstructured":"Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48(11):2293\u2013300. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2006.07.059\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"934_CR16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1161\/01.HYP.0000079505.25750.11","volume":"42","author":"L Mosso","year":"2003","unstructured":"Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J, et al. Primary aldosteronism and hypertensive disease. Hypertension. 2003;42(2):161\u20135. \n                      https:\/\/doi.org\/10.1161\/01.HYP.0000079505.25750.11\n                      \n                    .","journal-title":"Hypertension"},{"issue":"6","key":"934_CR17","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","volume":"40","author":"DA Calhoun","year":"2002","unstructured":"Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40(6):892\u20136.","journal-title":"Hypertension"},{"issue":"14","key":"934_CR18","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","volume":"69","author":"S Monticone","year":"2017","unstructured":"Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, et al. Prevalence and clinical manifestations of primary Aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017;69(14):1811\u201320. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2017.01.052\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"934_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1440-1681.1985.tb02641.x","volume":"12","author":"SM Hamlet","year":"1985","unstructured":"Hamlet SM, Tunny TJ, Woodland E, Gordon RD. Is aldosterone\/renin ratio useful to screen a hypertensive population for primary aldosteronism? Clin Exp Pharmacol Physiol. 1985;12(3):249\u201352.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"3","key":"934_CR20","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1210\/jc.2003-031337","volume":"89","author":"P Mulatero","year":"2004","unstructured":"Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89(3):1045\u201350. \n                      https:\/\/doi.org\/10.1210\/jc.2003-031337\n                      \n                    .","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"934_CR21","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P Milliez","year":"2005","unstructured":"Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8):1243\u20138. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2005.01.015\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"934_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","volume":"6","author":"S Monticone","year":"2018","unstructured":"Monticone S, D'Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6(1):41\u201350. \n                      https:\/\/doi.org\/10.1016\/S2213-8587(17)30319-4\n                      \n                    .","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"934_CR23","doi-asserted-by":"publisher","first-page":"5070","DOI":"10.1210\/jc.2005-0681","volume":"90","author":"M Stowasser","year":"2005","unstructured":"Stowasser M, Sharman J, Leano R, Gordon RD, Ward G, Cowley D, et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab. 2005;90(9):5070\u20136. \n                      https:\/\/doi.org\/10.1210\/jc.2005-0681\n                      \n                    .","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"934_CR24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","volume":"168","author":"C Catena","year":"2008","unstructured":"Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008;168(1):80\u20135. \n                      https:\/\/doi.org\/10.1001\/archinternmed.2007.33\n                      \n                    .","journal-title":"Arch Intern Med"},{"issue":"1","key":"934_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","volume":"6","author":"GL Hundemer","year":"2018","unstructured":"Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6(1):51\u20139. \n                      https:\/\/doi.org\/10.1016\/S2213-8587(17)30367-4\n                      \n                    .","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12 Pt 2","key":"934_CR26","first-page":"1610","volume":"13","author":"M Stowasser","year":"1995","unstructured":"Stowasser M, Bachmann AW, Jonsson JR, Tunny TJ, Klemm SA, Gordon RD. Clinical, biochemical and genetic approaches to the detection of familial hyperaldosteronism type I. J Hypertens. 1995;13(12 Pt 2):1610\u20133.","journal-title":"J Hypertens"},{"issue":"5","key":"934_CR27","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1440-1681.1992.tb00462.x","volume":"19","author":"M Stowasser","year":"1992","unstructured":"\u2022\u2022 Stowasser M, Gordon RD, Tunny TJ, Klemm SA, Finn WL, Krek AL. Familial hyperaldosteronism type II: five families with a new variety of primary aldosteronism. Clin Exp Pharmacol Physiol. 1992;19(5):319\u201322 This was the first paper to coin the term \u201cFH-II\u201d.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"5","key":"934_CR28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1440-1681.1991.tb01446.x","volume":"18","author":"RD Gordon","year":"1991","unstructured":"\u2022\u2022 Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Finn WL, Krek AL. Clinical and pathological diversity of primary aldosteronism, including a new familial variety. Clin Exp Pharmacol Physiol. 1991;18(5):283\u20136 This was the first paper to describe a group of families with non-glucocorticoid-suppressible PA.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"9","key":"934_CR29","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1097\/00004872-200018090-00002","volume":"18","author":"M Stowasser","year":"2000","unstructured":"Stowasser M, Gordon RD. Primary aldosteronism: learning from the study of familial varieties. J Hypertens. 2000;18(9):1165\u201376.","journal-title":"J Hypertens"},{"issue":"13","key":"934_CR30","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1055\/s-0035-1564166","volume":"47","author":"HE Korah","year":"2015","unstructured":"Korah HE, Scholl UI. An update on familial hyperaldosteronism. Horm Metab Res. 2015;47(13):941\u20136. \n                      https:\/\/doi.org\/10.1055\/s-0035-1564166\n                      \n                    .","journal-title":"Horm Metab Res"},{"issue":"12","key":"934_CR31","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1055\/s-0043-120066","volume":"49","author":"UI Scholl","year":"2017","unstructured":"Scholl UI. Unanswered questions in the genetic basis of primary aldosteronism. Horm Metab Res. 2017;49(12):963\u20138. \n                      https:\/\/doi.org\/10.1055\/s-0043-120066\n                      \n                    .","journal-title":"Horm Metab Res"},{"issue":"9","key":"934_CR32","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/jhh.2010.93","volume":"25","author":"KJ Carss","year":"2011","unstructured":"Carss KJ, Stowasser M, Gordon RD, O'Shaughnessy KM. Further study of chromosome 7p22 to identify the molecular basis of familial hyperaldosteronism type II. J Hum Hypertens. 2011;25(9):560\u20134. \n                      https:\/\/doi.org\/10.1038\/jhh.2010.93\n                      \n                    .","journal-title":"J Hum Hypertens"},{"issue":"8","key":"934_CR33","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1097\/01.hjh.0000174299.66369.26","volume":"23","author":"A So","year":"2005","unstructured":"So A, Duffy DL, Gordon RD, Jeske YW, Lin-Su K, New MI, et al. Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. J Hypertens. 2005;23(8):1477\u201384.","journal-title":"J Hypertens"},{"issue":"8","key":"934_CR34","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1097\/HJH.0b013e3283028352","volume":"26","author":"N Sukor","year":"2008","unstructured":"Sukor N, Mulatero P, Gordon RD, So A, Duffy D, Bertello C, et al. Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families. J Hypertens. 2008;26(8):1577\u201382. \n                      https:\/\/doi.org\/10.1097\/HJH.0b013e3283028352\n                      \n                    .","journal-title":"J Hypertens"},{"issue":"9","key":"934_CR35","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1210\/jcem.83.9.5086.","volume":"83","author":"DJ Torpy","year":"1998","unstructured":"Torpy DJ, Gordon RD, Lin JP, Huggard PR, Taymans SE, Stowasser M, et al. Familial hyperaldosteronism type II: description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene. J Clin Endocrinol Metab. 1998;83(9):3214\u20138. \n                      https:\/\/doi.org\/10.1210\/jcem.83.9.5086.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"934_CR36","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1210\/jcem.83.3.4668-10","volume":"83","author":"DJ Torpy","year":"1998","unstructured":"Torpy DJ, Stratakis CA, Gordon RD. Linkage analysis of familial hyperaldosteronism type II--absence of linkage to the gene encoding the angiotensin II receptor type 1. J Clin Endocrinol Metab. 1998;83(3):1046. \n                      https:\/\/doi.org\/10.1210\/jcem.83.3.4668-10\n                      \n                    .","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"934_CR37","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/j.1440-1681.2008.04882.x","volume":"35","author":"YW Jeske","year":"2008","unstructured":"Jeske YW, So A, Kelemen L, Sukor N, Willys C, Bulmer B, et al. Examination of chromosome 7p22 candidate genes RBaK, PMS2 and GNA12 in familial hyperaldosteronism type II. Clin Exp Pharmacol Physiol. 2008;35(4):380\u20135. \n                      https:\/\/doi.org\/10.1111\/j.1440-1681.2008.04882.x\n                      \n                    .","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"8","key":"934_CR38","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1210\/jc.2008-0594","volume":"93","author":"DS Geller","year":"2008","unstructured":"Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Kashgarian M, Lifton RP. A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab. 2008;93(8):3117\u201323. \n                      https:\/\/doi.org\/10.1210\/jc.2008-0594\n                      \n                    .","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"934_CR39","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1210\/jc.2008-1241","volume":"93","author":"P Mulatero","year":"2008","unstructured":"Mulatero P. A new form of hereditary primary aldosteronism: familial hyperaldosteronism type III. J Clin Endocrinol Metab. 2008;93(8):2972\u20134. \n                      https:\/\/doi.org\/10.1210\/jc.2008-1241\n                      \n                    .","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"934_CR40","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1210\/en.2011-1733","volume":"153","author":"K Oki","year":"2012","unstructured":"Oki K, Plonczynski MW, Luis Lam M, Gomez-Sanchez EP, Gomez-Sanchez CE. Potassium channel mutant KCNJ5 T158A expression in HAC-15 cells increases aldosterone synthesis. Endocrinology. 2012;153(4):1774\u201382. \n                      https:\/\/doi.org\/10.1210\/en.2011-1733\n                      \n                    .","journal-title":"Endocrinology"},{"issue":"6","key":"934_CR41","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1172\/JCI61996","volume":"122","author":"C Hu","year":"2012","unstructured":"Hu C, Rusin CG, Tan Z, Guagliardo NA, Barrett PQ. Zona glomerulosa cells of the mouse adrenal cortex are intrinsic electrical oscillators. J Clin Invest. 2012;122(6):2046\u201353. \n                      https:\/\/doi.org\/10.1172\/JCI61996\n                      \n                    .","journal-title":"J Clin Invest"},{"key":"934_CR42","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1210\/en.2016-1170","volume":"157","author":"EN Reimer","year":"2016","unstructured":"Reimer EN, Walenda G, Seidel E, Scholl UI. CACNA1H mutant calcium channel causes autonomous aldosterone production in HAC15 cells and is inhibited by Mibefradil. Endocrinology. 2016;157:3016\u201322. \n                      https:\/\/doi.org\/10.1210\/en.2016-1170\n                      \n                    .","journal-title":"Endocrinology"},{"issue":"2","key":"934_CR43","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1161\/HYPERTENSIONAHA.114.03419","volume":"64","author":"FL Fernandes-Rosa","year":"2014","unstructured":"Fernandes-Rosa FL, Williams TA, Riester A, Steichen O, Beuschlein F, Boulkroun S, et al. Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma. Hypertension. 2014;64(2):354\u201361. \n                      https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.114.03419\n                      \n                    .","journal-title":"Hypertension"},{"key":"934_CR44","doi-asserted-by":"publisher","first-page":"E1089","DOI":"10.1210\/jc.2015-2149","volume":"100","author":"L Lenzini","year":"2015","unstructured":"Lenzini L, Rossitto G, Maiolino G, Letizia C, Funder JW, Rossi GP. A meta-analysis of somatic KCNJ5 K channel mutations in 1636 patients with an aldosterone-producing adenoma. J Clin Endocrinol Metab. 2015;100:E1089\u201395. \n                      https:\/\/doi.org\/10.1210\/jc.2015-2149\n                      \n                    .","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"934_CR45","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/ng.2716","volume":"45","author":"EA Azizan","year":"2013","unstructured":"Azizan EA, Poulsen H, Tuluc P, Zhou J, Clausen MV, Lieb A, et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet. 2013;45(9):1055\u201360. \n                      https:\/\/doi.org\/10.1038\/ng.2716\n                      \n                    .","journal-title":"Nat Genet"},{"issue":"4","key":"934_CR46","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/ng.2550","volume":"45","author":"F Beuschlein","year":"2013","unstructured":"\u2022 Beuschlein F, Boulkroun S, Osswald A, Wieland T, Nielsen HN, Lichtenauer UD, et al. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet. 2013;45(4):440\u20134. \n                      https:\/\/doi.org\/10.1038\/ng.2550\n                      \n                     This paper described the occurrence of somatic ATP1A1 and ATP2B3 mutations in aldosterone-producing adenomas.","journal-title":"Nat Genet"},{"issue":"10","key":"934_CR47","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.1210\/jc.2018-01004","volume":"103","author":"K Nanba","year":"2018","unstructured":"Nanba K, Omata K, Else T, Beck PCC, Nanba AT, Turcu AF, et al. Targeted molecular characterization of aldosterone-producing adenomas in white Americans. J Clin Endocrinol Metab. 2018;103(10):3869\u201376. \n                      https:\/\/doi.org\/10.1210\/jc.2018-01004\n                      \n                    .","journal-title":"J Clin Endocrinol Metab"},{"issue":"33","key":"934_CR48","doi-asserted-by":"publisher","first-page":"E4591","DOI":"10.1073\/pnas.1505529112","volume":"112","author":"K Nishimoto","year":"2015","unstructured":"Nishimoto K, Tomlins SA, Kuick R, Cani AK, Giordano TJ, Hovelson DH, et al. Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands. Proc Natl Acad Sci U S A. 2015;112(33):E4591\u20139. \n                      https:\/\/doi.org\/10.1073\/pnas.1505529112\n                      \n                    .","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"934_CR49","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1161\/HYPERTENSIONAHA.118.11086","volume":"72","author":"K Omata","year":"2018","unstructured":"Omata K, Satoh F, Morimoto R, Ito S, Yamazaki Y, Nakamura Y, et al. Cellular and genetic causes of idiopathic hyperaldosteronism. Hypertension. 2018;72(4):874\u201380. \n                      https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.118.11086\n                      \n                    .","journal-title":"Hypertension"},{"issue":"6364","key":"934_CR50","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/356057a0","volume":"356","author":"A Thiemann","year":"1992","unstructured":"Thiemann A, Grunder S, Pusch M, Jentsch TJ. A chloride channel widely expressed in epithelial and non-epithelial cells. Nature. 1992;356(6364):57\u201360. \n                      https:\/\/doi.org\/10.1038\/356057a0\n                      \n                    .","journal-title":"Nature"},{"issue":"Pt 3","key":"934_CR51","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1113\/jphysiol.2003.060046","volume":"555","author":"L Zuniga","year":"2004","unstructured":"Zuniga L, Niemeyer MI, Varela D, Catalan M, Cid LP, Sepulveda FV. The voltage-dependent ClC-2 chloride channel has a dual gating mechanism. J Physiol. 2004;555(Pt 3):671\u201382. \n                      https:\/\/doi.org\/10.1113\/jphysiol.2003.060046\n                      \n                    .","journal-title":"J Physiol"},{"issue":"10","key":"934_CR52","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nrn3819","volume":"15","author":"K Kaila","year":"2014","unstructured":"Kaila K, Price TJ, Payne JA, Puskarjov M, Voipio J. Cation-chloride cotransporters in neuronal development, plasticity and disease. Nat Rev Neurosci. 2014;15(10):637\u201354. \n                      https:\/\/doi.org\/10.1038\/nrn3819\n                      \n                    .","journal-title":"Nat Rev Neurosci"},{"issue":"10","key":"934_CR53","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1007\/s00424-013-1286-0","volume":"465","author":"G Stolting","year":"2013","unstructured":"Stolting G, Teodorescu G, Begemann B, Schubert J, Nabbout R, Toliat MR, et al. Regulation of ClC-2 gating by intracellular ATP. Pflugers Arch. 2013;465(10):1423\u201337. \n                      https:\/\/doi.org\/10.1007\/s00424-013-1286-0\n                      \n                    .","journal-title":"Pflugers Arch"},{"issue":"6004","key":"934_CR54","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1126\/science.1195230","volume":"330","author":"L Feng","year":"2010","unstructured":"Feng L, Campbell EB, Hsiung Y, MacKinnon R. Structure of a eukaryotic CLC transporter defines an intermediate state in the transport cycle. Science. 2010;330(6004):635\u201341. \n                      https:\/\/doi.org\/10.1126\/science.1195230\n                      \n                    .","journal-title":"Science"},{"issue":"6406","key":"934_CR55","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/360759a0","volume":"360","author":"S Grunder","year":"1992","unstructured":"Grunder S, Thiemann A, Pusch M, Jentsch TJ. Regions involved in the opening of CIC-2 chloride channel by voltage and cell volume. Nature. 1992;360(6406):759\u201362. \n                      https:\/\/doi.org\/10.1038\/360759a0\n                      \n                    .","journal-title":"Nature"},{"issue":"Pt 2","key":"934_CR56","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1113\/jphysiol.2002.026096","volume":"544","author":"D Varela","year":"2002","unstructured":"Varela D, Niemeyer MI, Cid LP, Sepulveda FV. Effect of an N-terminus deletion on voltage-dependent gating of the ClC-2 chloride channel. J Physiol. 2002;544(Pt 2):363\u201372.","journal-title":"J Physiol"},{"issue":"7","key":"934_CR57","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1093\/emboj\/16.7.1582.","volume":"16","author":"SE Jordt","year":"1997","unstructured":"Jordt SE, Jentsch TJ. Molecular dissection of gating in the ClC-2 chloride channel. EMBO J. 1997;16(7):1582\u201392. \n                      https:\/\/doi.org\/10.1093\/emboj\/16.7.1582.","journal-title":"EMBO J"},{"issue":"2","key":"934_CR58","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1152\/physrev.00030.2003","volume":"84","author":"A Spat","year":"2004","unstructured":"Spat A, Hunyady L. Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol Rev. 2004;84(2):489\u2013539. \n                      https:\/\/doi.org\/10.1152\/physrev.00030.2003\n                      \n                    .","journal-title":"Physiol Rev"},{"issue":"2","key":"934_CR59","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1210\/endo.141.2.7328","volume":"141","author":"A Chorvatova","year":"2000","unstructured":"Chorvatova A, Gendron L, Bilodeau L, Gallo-Payet N, Payet MD. A Ras-dependent chloride current activated by adrenocorticotropin in rat adrenal zona glomerulosa cells. Endocrinology. 2000;141(2):684\u201392. \n                      https:\/\/doi.org\/10.1210\/endo.141.2.7328\n                      \n                    .","journal-title":"Endocrinology"},{"issue":"Suppl 1","key":"934_CR60","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/S0140-6736(15)60377-4.","volume":"385","author":"C Maniero","year":"2015","unstructured":"Maniero C, Zhou J, Shaikh LH, Azizan EA, McFarlane I, Neogi S, et al. Role of ANO4 in regulation of aldosterone secretion in the zona glomerulosa of the human adrenal gland. Lancet. 2015;385(Suppl 1):S62. \n                      https:\/\/doi.org\/10.1016\/S0140-6736(15)60377-4.","journal-title":"Lancet"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-019-0934-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-019-0934-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-019-0934-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T04:49:54Z","timestamp":1590036594000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-019-0934-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["934"],"URL":"https:\/\/doi.org\/10.1007\/s11906-019-0934-y","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"4 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Heinrich Heine University D\u00fcsseldorf has filed a patent application: EP17209972, Diagnosis and Therapy of Primary Aldosteronism, with UIS as an inventor. Other authors declare no conflicts of interest relevant to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"31"}}